This page provides informaton about BCCH's Provincial Mental Health Metabolic Program and about monitoring for the metabolic effects of atypical antipsychotic medication.
Information for health-care providers
The following handouts are designed for health-care professionals caring for children or adolescents who will be starting or who are already using atypical antipsychotic medications:
A more complete listing of resources for professionals using second-generation antipsychotic medications in children is available
Information for parents and caregivers
The following handouts are designed to give to families of children or adolescents who will be starting or who are already using atypical antipsychotic medications:
A more complete listing of resources for parents and caregivers of children using second-generation antipsychotic medications is available
The Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA) Guideline Project of the Canadian Academy of Child and Adolescent Psychiatry have published guidelines for monitoring for complications and safety of second-generation antipsychotics in chilldren and adolescents in Canada: